MB is a PhD student and part-time employee of MSD France. VL, LL, and CC are full-time employees of MSD France.
EVG, LL, and MB designed and oversaw the study, and performed the statistical analysis. MB, EVG, LL and GdP wrote the manuscript. JB, JdB, BF, VL and CCV made suggestions to improve the study, and revised the manuscript. GdP, JB, BF, and JdB were members of the study Scientific Committee. All authors read and approved the final manuscript.
This pilot study, conducted on a 1/97th representative sample of French claims data, prepared a project to assess the effectiveness of Montelukast (MTL-4) as add-on therapy for asthma in infants (6–24 months) compared to inhaled corticosteroids (ICS), based on real-world data. Due to the very recent opening of French claims data for effectiveness research, and the complex structure of this data source, we first tested the feasibility of identifying infants with asthma and outcome criteria, and the ability to perform relevant comparisons.
We identified a cohort of infants with uncontrolled asthma and receiving ≥2 consecutive dispensations of any respiratory drug (R03 ATC classification) during a 6-month period. Uncontrolled asthma was identified either from exacerbations or from markers of acute loss of asthma control; date of occurrence of an event (exacerbation and/or acute loss of asthma control) was defined as index date. The study groups comprised infants receiving MTL-4 +/− ICS (MTL-4 group) or ICS without MTL-4 (ICS group) at index date. These two groups were matched on gender, age, quarter of index date, therapy before index date, past asthma-related hospitalization (ever), and were followed for 6 months. The outcome was the rate of infants with uncontrolled asthma, defined as above.
This pilot cohort study included 1,149 infants with asthma (mean age 14.1 months, 64% boys). Of these, 51 and 768 were assigned to the MTL-4 and ICS groups, respectively. Uncontrolled asthma occurred in 78.8% and 78.4% of infants in these groups, respectively (oral corticosteroids were dispensed to 49% and 61%, respectively). Assessment of uncontrolled asthma, exposure to MTL-4 and ICS, and occurrence of outcomes were achieved. For the development of matching criteria, we defined a new marker of severity (therapeutic typologies).
These data support the feasibility of the final project, to be conducted on claims data from the whole French population. We also showed that, with appropriate methodology and by using valid criteria, French claims data are an adequate resource for conducting comparative effectiveness studies in pediatric asthma. Finally, the algorithm used to identify infants with asthma could be applied to other studies using claims data.
HAS. Asthme de l’enfant de moins de 36 mois : diagnostic, prise en charge et traitement en dehors des épisodes aigus. Synthèse des recommandations professionnelles 2009. http://www.has-sante.fr/portail/upload/docs/application/pdf/2009-05/asthme_de_lenfant_de_moins_de_36_mois_-_synthese_des_recommandations.pdf
The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med. 2000;343:1054–63. CrossRef
Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2014 http://www.ginasthma.org
British Thoracic Society and Scottish Intercollegiate Guidelines Network. British guidelines on the management of asthma - A national clinical guideline. 2011 https://www.brit-thoracic.org.uk/guidelines-and-quality-standards/asthmaguideline/
Expert Panel. Report 3: Guidelines for the Diagnosis and Management of Asthma. 2007 http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm
Lougheed MD, Lemiere C, Dell SD, Ducharme FM, Fitzgerald JM, Leigh R, et al. Canadian thoracic society asthma management continuum - consensus summary for children six years of age and over, and adults. Can Respir J. 2010;2010(17):15–24. CrossRef
Bukstein DA, Luskin AT, Bernstein A. ‘Real-world’ effectiveness of daily controller medicine in children with mild persistent asthma. Ann Allerg Asthma Immunol. 2003;90:543–9. CrossRef
Afrite A, Allonier C, Com-Ruelle L, Le Guen N. L’asthme en France en 2006: prévalence et contrôle des symptômes. IRDES questions d’Economie de la Santé. 2008;138:1–8.
Godard P, De Blic J, Huas D, Boucot I, Pribil C. ER’ASTHME: évaluation du contrôle de l’asthme chez 410 enfants âgés de 6 à 14 ans en médecine générale. Revue des Maladies Respiratoires. 2006;23(HS1):8–12.
Martin-Latry K, Bégaud B. Pharmacoepidemiological research using French reimbursement databases: yes we can! Pharmacoepidemiol Drug Sa. 2010;19:256–65. CrossRef
Reddel HK, Taylor DR, Bateman ED, Boulet L-P, Boushey HA, Busse WW, et al. An official american thoracic society/european respiratory society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180:59–99. CrossRefPubMed
Strom BL. Methodologic challenges to studying patient safety and comparative effectiveness. Med Care. 2007;45(10 Supl 2):13–5. CrossRef
- Effectiveness of Montelukast on asthma control in infants: methodology of a French claims data study
Gérard de Pouvourville
Jacques de Blic
Eric Van Ganse
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II